A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety and Efficacy Study with Open-label Extension Period of Tesomet in Adult and Adolescent Subjects with Prader-Willi Syndrome
Latest Information Update: 21 Dec 2022
At a glance
- Drugs Metoprolol/tesofensine (Primary)
- Indications Prader-Willi syndrome
- Focus Therapeutic Use
- Sponsors Saniona
Most Recent Events
- 29 Mar 2022 Status changed from recruiting to suspended, according to a Saniona media release.
- 29 Mar 2022 According to a Saniona media release, the decision to voluntarily pause the Phase 2b clinical trial of Tesomet for PWS is not related to the safety or efficacy of Tesomet and is entirely due to funding limitations.
- 31 Dec 2021 Planned number of patients changed to 120.